{"schema_version":"secwatch.filing_event.v1","accession":"0001650664-25-000086","form_type":"8-K","ticker":"EDIT","cik":"0001650664","company_name":"Editas Medicine, Inc.","filed_at":"2025-06-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.201091+00:00","generated_at":"2026-05-20T02:58:39.682401+00:00","sec_items":["5.02","5.03","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Editas Medicine stockholders approve increase in authorized shares and amend 2015 Stock Incentive Plan at annual meeting","bullets":["Stockholders approved amendment to increase authorized common stock from 195M to 390M shares; total capital stock from 200M to 395M.","Stockholders approved amendment and restatement of 2015 Stock Incentive Plan, extending term to 10 years and eliminating evergreen provision.","Re-elected Jessica Hopfield, Ph.D., and David Scadden, M.D. as Class III directors until the 2028 annual meeting.","Advisory vote on executive compensation passed with ~60% for; one-year frequency for future say-on-pay votes approved.","Ratified Ernst & Young LLP as independent registered public accounting firm for fiscal year 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001650664-25-000086","json":"https://secwatch.observer/filing/0001650664-25-000086.json","markdown":"https://secwatch.observer/filing/0001650664-25-000086.md","text":"https://secwatch.observer/filing/0001650664-25-000086.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650664/000165066425000086/0001650664-25-000086-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650664/000165066425000086/edit-20250529.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T02:58:39.682401+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"40e9f2ef65c3042bbba915b745e622c2da6e2581","claim":"Editas Medicine, Inc.: Increased authorized shares of capital stock from 200,000,000 to 395,000,000 and common stock from 195,000,000 to 390,000,000 (effective 2025-06-02).","evidence_excerpt":"At the Annual Meeting, the Company’s stockholders approved an amendment to the Company’s Restated Certificate of Incorporation (the “Certificate of Amendment”) to increase the number of authorized shares of the Company’s capital stock from 200,000,000 to 395,000,000 and the number of authorized shares of the Company’s common stock from 195,000,000 to 390,000,000. The additional common stock authorized by the Certificate of Amendment has rights identical to the Company’s currently outstanding common stock. The Company filed the Certificate of Amendment, which was effective upon filing, with the Secretary of State of the State of Delaware on June 2, 2025.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1650664/000165066425000086/0001650664-25-000086-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2025-06-02"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}